What does PD-L1 positive or negative mean?

被引:263
|
作者
Ribas, Antoni [1 ,2 ]
Hu-Lieskovan, Siwen [1 ,2 ]
机构
[1] Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, JCCC, Los Angeles, CA 90095 USA
来源
JOURNAL OF EXPERIMENTAL MEDICINE | 2016年 / 213卷 / 13期
基金
美国国家卫生研究院;
关键词
CELL LUNG-CANCER; ADAPTIVE IMMUNE RESISTANCE; ADVANCED MELANOMA; UNTREATED MELANOMA; CLINICAL ACTIVITY; HODGKIN LYMPHOMA; OPEN-LABEL; EXPRESSION; BLOCKADE; NIVOLUMAB;
D O I
10.1084/jem.20161462
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Expression of the programmed death-1 (PD-1) ligand 1 (PD-L1) is used to select patients and analyze responses to anti-PD-1/L1 antibodies. The expression of PD-L1 is regulated in different ways, which leads to a different significance of its presence or absence. PD-L1 positivity may be a result of genetic events leading to constitutive PD-L1 expression on cancer cells or inducible PD-L1 expression on cancer cells and noncancer cells in response to a T cell infiltrate. A tumor may be PD-L1 negative because it has no T cell infiltrate, which may be reversed with an immune response. Finally, a tumor that is unable to express PD-L1 because of a genetic event will always be negative for PD-L1 on cancer cells.
引用
收藏
页码:2835 / 2840
页数:6
相关论文
共 50 条
  • [21] JAK2 and PD-L1 amplification enhance the dynamic expression of PD-L1 in triple negative breast cancer
    Chen, M.
    Pockaj, B.
    Andreozzi, M.
    Barrett, M. T.
    Ocal, I. T.
    McCullough, A. E.
    Krishna, S.
    Anderson, K. S.
    CANCER RESEARCH, 2017, 77
  • [22] PD-L1 immunostaining: what pathologists need to know
    Akhtar, Mohammed
    Rashid, Sameera
    Al-Bozom, Issam A.
    DIAGNOSTIC PATHOLOGY, 2021, 16 (01)
  • [23] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
    Monneur, Audrey
    Goncalves, Anthony
    Bertucci, Francois
    BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272
  • [24] Beyond inhibition against the PD-1/PD-L1 pathway: development of PD-L1 inhibitors targeting internalization and degradation of PD-L1
    Guo, Jiazheng
    Yu, Fengyi
    Zhang, Kuojun
    Jiang, Sheng
    Zhang, Xiangyu
    Wang, Tianyu
    RSC MEDICINAL CHEMISTRY, 2024, 15 (04): : 1096 - 1108
  • [25] Blockade of CCL2 expression overcomes intrinsic PD-1/PD-L1 inhibitor-resistance in transglutaminase 2-induced PD-L1 positive triple negative breast cancer
    Choi, Junyoung
    Lee, Hee Jin
    Yoon, Shinkyo
    Ryu, Hyun-Min
    Lee, Eunjin
    Jo, Yujin
    Seo, Seyoung
    Kim, Deokhoon
    Lee, Chang Hoon
    Kim, Wanlim
    Ha, Joo Young
    Kim, Soo-Youl
    Gong, Gyungyub
    Jung, Kyung Hae
    Park, Sook Ryun
    Kim, Sang-We
    Park, Kang-Seo
    Lee, Dae Ho
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (09): : 2878 - +
  • [26] Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
    Bai, Jie
    Gao, Zhitao
    Li, Xiang
    Dong, Liang
    Han, Weidong
    Nie, Jing
    ONCOTARGET, 2017, 8 (66) : 110693 - 110707
  • [27] PD-L1 Amino Acid Position 88 Represents a Hotspot for PD-L1 Stability With Relevance for PD-L1 Inhibition
    Claass, Luise Victoria
    Schultheiss, Christoph
    Scholz, Rebekka
    Paschold, Lisa
    Simnica, Donjete
    Heinemann, Volker
    Stintzing, Sebastian
    Binder, Mascha
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [28] Serum PD-1/PD-L1 Levels, Tumor Expression and PD-L1 Somatic Mutations in HER2-Positive and Triple Negative Normal-Like Feline Mammary Carcinoma Subtypes
    Nascimento, Catarina
    Urbano, Ana Catarina
    Gameiro, Andreia
    Ferreira, Joao
    Correia, Jorge
    Ferreira, Fernando
    CANCERS, 2020, 12 (06)
  • [29] Significance of PD-L1 expressing tumor cells in the combined positive score with triple negative breast cancer
    Evans, Tiffany
    Hund, Stephanie
    Krohn, Darlene
    Emancipator, Kenneth
    Juco, Jonathon
    Portier, Bryce
    Tabuena-Frolli, Siena
    Kulangara, Karina
    CANCER RESEARCH, 2021, 81 (04)
  • [30] Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?
    Sundararajan, Srinath
    Vogelzang, Nicholas J.
    FUTURE ONCOLOGY, 2015, 11 (16) : 2299 - 2306